Laurel Wealth Advisors (North Carolina)’s Vertex Pharmaceuticals VRTX Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10	Closed	-$4.53K	–	651
2025 Q4	$4.53K	Buy	+10	New	+$4.31K	﹤0.01%	549
2025 Q2	–	Sell	-10	Closed	-$4.85K	–	664
2025 Q1	$4.85K	Hold	10	–	–	﹤0.01%	539
2024 Q4	$4.03K	Hold	10	–	–	﹤0.01%	576
2024 Q3	$4.65K	Sell	10 -3	-23%	-$1.44K	﹤0.01%	523
2024 Q2	$6.09K	Hold	13	–	–	﹤0.01%	464
2024 Q1	$5.43K	Buy	+13	New	+$5.5K	﹤0.01%	480

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s VRTX Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 10 shares — an estimated $4.53K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in VRTX in Q1 2024 and held it in 6 quarters. The position peaked at $6.09K in Q2 2024. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Laurel Wealth Advisors (North Carolina) reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 10 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.53K.
Laurel Wealth Advisors (North Carolina) first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Laurel Wealth Advisors (North Carolina)'s Vertex Pharmaceuticals position peaked at $6.09K in Q2 2024.
1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.